[1]李 朝,周玉明,姜 茹,等.嘌呤能受体在卵巢癌中的预后价值及肿瘤免疫浸润分析[J].医学信息,2024,37(17):1-10.[doi:10.3969/j.issn.1006-1959.2024.17.001]
　LI Zhao,ZHOU Yu-ming,JIANG Ru,et al.Prognostic Value of Purinergic Receptors in Ovarian Cancer and Analysis of Tumor Immune Infiltration[J].Journal of Medical Information,2024,37(17):1-10.[doi:10.3969/j.issn.1006-1959.2024.17.001]
点击复制

嘌呤能受体在卵巢癌中的预后价值及肿瘤免疫浸润分析()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年17期
页码:
1-10
栏目:
生物信息学
出版日期:
2024-09-01

文章信息/Info

Title:
Prognostic Value of Purinergic Receptors in Ovarian Cancer and Analysis of Tumor Immune Infiltration
文章编号:
1006-1959（2024）17-0001-10
作者:
李 朝1;  周玉明2; 姜 茹2; 于运亮2
1.临清市人民医院检验科，山东 聊城 252600；2.滨州医学院烟台附属医院检验科，山东 烟台 264100
Author(s):
LI Zhao1; ZHOU Yu-ming2; JIANG Ru2; YU Yun-liang2
1.Department of Medical Laboratory,Linqing People’s Hospital,Liaocheng 252600,Shandong,China;2.Department of Medical Laboratory,Yantai Affiliated Hospital of Binzhou Medical University,Yantai 264100,Shandong,China
关键词:
嘌呤能受体; 浆液性卵巢癌; 数据库; 预后; 免疫浸润
Keywords:
Purinergic receptors; Ovarian serous cancer; Database; Prognosis; Immune infiltration
分类号:
R737.31
DOI:
10.3969/j.issn.1006-1959.2024.17.001
文献标志码:
A
摘要:
目的 构建浆液性卵巢癌（OV）嘌呤能受体家族基因的预后模型，分析基因的表达与免疫细胞浸润及常用化疗药物的关系。方法 下载癌症基因图谱（TCGA）等数据库中15个嘌呤能受体家族基因的表达谱数据及临床信息，利用LASSO回归分析筛选与OV患者生存有关的基因，根据风险值对患者分组并使用Kaplan-Meier Plotter对关键基因进行生存分析。应用多因素Cox回归分析构建基于TCGA-OV数据集的预后模型，绘制列线图和校准曲线。利用TIMER、xCell算法进行免疫浸润分析。利用TIDE算法分析基因的表达与免疫检查点阻断（ICB）治疗的相关性。利用TCGA联合癌症药物敏感性基因组学（GDSC）数据库进行药物敏感性分析。结果 LASSO回归分析筛选得到6个嘌呤能受体家族基因与OV患者预后有关。多因素Cox回归分析显示，P2RX6、P2RY12、P2RY14、年龄和种族是OV患者独立的预后因素（P＜0.05）。P2RX6和P2RY14在OV中表达下调（P＜0.05）。P2RY14的表达不仅与PDCD1、CTLA4、TIGIT等多种免疫检查点有关，还与紫杉醇、顺铂、环磷酰胺、多西他赛的半抑制浓度（IC50）呈负相关。P2RY14相关基因主要参与免疫细胞激活、分化、增殖等生物学过程。结论 基于TCGA数据库构建OV患者的预后模型，经筛选得出P2RY14可作为OV患者预后独立危险因素，可为指导OV的免疫治疗提供新的思路和方向。
Abstract:
Objective To construct a prognostic model of purinergic receptor family genes in serous ovarian cancer (OV), and to analyze the relationship between gene expression and immune cell infiltration and commonly used chemotherapeutic drugs.Methods The expression profile data and clinical information of 15 purinergic receptor family genes in databases such as the Cancer Genome Atlas (TCGA) were downloaded. LASSO regression analysis was used to screen genes related to the survival of OV patients. Patients were grouped according to the risk value and Kaplan-Meier Plotter was used to analyze the survival of key genes. Multivariate Cox regression analysis was used to construct a prognostic model based on TCGA-OV data set, and the nomogram and calibration curve were drawn. Immune infiltration analysis was performed using TIMER and xCell algorithms. TIDE algorithm was used to analyze the correlation between gene expression and immune checkpoint blockade (ICB) treatment. Drug sensitivity analysis was performed using the TCGA combined with Genomics of Drug Sensitivity in Cancer (GDSC) database.Results Six purinergic receptor family genes screened by LASSO regression analysis were related to the prognosis of OV patients. Multivariate Cox regression analysis showed that P2RX6, P2RY12, P2RY14, age and race were independent prognostic factors for OV patients (P<0.05). The expression of P2RX6 and P2RY14 was down-regulated in OV (P<0.05). The expression of P2RY14 was not only related to PDCD1, CTLA4, TIGIT and other immune checkpoints, but also negatively correlated with the half inhibitory concentration (IC50) of paclitaxel, cisplatin, cyclophosphamide and docetaxel. P2RY14-related genes were mainly involved in biological processes such as immune cell activation, differentiation, and proliferation.Conclusion Based on the TCGA database, the prognostic model of OV patients is constructed. After screening, P2RY14 can be used as an independent risk factor for the prognosis of OV patients, which can provide new ideas and directions for guiding the immunotherapy of OV.

参考文献/References:

[1]祝彩霞,袁林静,杨娟,等.高级别浆液性卵巢癌中细胞角蛋白19的表达和意义[J].广东医学,2022,43(3):345-350.[2]Cibula D,Rob L,Mallmann P,et al.Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial[J].Gynecol Oncol,2021,162(3):652-660.[3]黄小珏,吴林桦,莫柳慧,等.基于ESTIMATE算法和生物信息学分析挖掘卵巢癌免疫治疗关键基因[J].广西医科大学学报,2020,37(5):897-901.[4]王佳晰,张师前.自体树突状细胞疫苗用于低突变负荷和“冷肿瘤”上皮性卵巢癌患者免疫治疗[J].中华医学杂志,2022,102(26):2029.[5]Mo J,Ruan S,Yang B,et al.A novel defined risk signature of endoplasmic reticulum stress-related genes for predicting the prognosis and immune infiltration status of ovarian cancer[J].J Zhejiang Univ Sci B,2023,24(1):64-77.[6]Zarrinmayeh H,Territo PR.Purinergic receptors of the central nervous system: Biology,PET ligands,and their applications[J].Mol Imaging,2020,19:1536012120927609.[7]Audrito V.Pancreatic cancer immune evasion mechanisms: the immunosuppressive role of P2RX1-negative neutrophils[J].Purinergic Signal,2021,17(2):173-174.[8]Wang X,Hu LP,Qin WT,et al.Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis[J].Nat Commun,2021,12(1):174.[9]Xu Y,Zou B,Fan B,et al.NcRNAs-mediated P2RX1 expression correlates with clinical outcomes and immune infiltration in patients with breast invasive carcinoma[J].Aging (Albany NY),2022,14(10):4471-4485.[10]Xu T,Xu S,Yao Y,et al.P2RY14 downregulation in lung adenocarcinoma: a potential therapeutic target associated with immune infiltration[J].J Thorac Dis,2022,14(2):515-535.[11]Yoshihara K,Tajima A,Komata D,et al.Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis[J].Cancer Sci,2009,100(8):1421-1428.[12]Zhang M,Chen Z,Wang Y,et al.The role of cancer-associated fibroblasts in ovarian cancer[J].Cancers (Basel),2022,14(11):2637.[13]耿辉,田国祥,王亚军,等.肿瘤浸润性免疫细胞分析数据库TIMER2.0的应用介绍[J].中国循证心血管医学杂志,2020,12(11):1283-1286,1301.[14]Lu K,Wang L,Fu Y,et al.Bioinformatics analysis identifies immune-related gene signatures and subtypes in diabetic nephropathy[J].Front Endocrinol (Lausanne),2022,13:1048139.[15]Kennedy C.The P2Y/P2X divide: How it began[J].Biochem Pharmacol,2021,187:114408.[16]Zhang WJ,Hu DX,Lin SJ,et al.Contribution of P2X purinergic receptor in cerebral ischemia injury[J].Brain Res Bull,2022,190:42-49.[17]徐庆娟,杨彬彬.基于 R 软件的 Lasso 回归在肿瘤信息基因选择中的应用[J].广西师范学院学报(自然科学版),2016,33(4):36-41.[18]Patritti Cram J,Wu J,Coover RA,et al.P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis[J].Elife,2022,11:e73511.[19]胡美娜,朱莉,曾亚悦,等.个体化卵巢癌新抗原的预测和免疫原性验证[J].现代医学,2022,50(8):995-1002.[20]崔彭华,李志艳,张玉娟,等.卵巢癌患者外周血Treg细胞和Th1、Th2细胞因子的变化及其与临床病理特征的关系[J].江苏大学学报(医学版),2019,29(2):153-156.

相似文献/References:

[1]范玲玲,王成海.浆液性卵巢癌SFRP2和MORC2的表达及其预后意义[J].医学信息,2026,39(05):16.[doi:10.3969/j.issn.1006-1959.2026.05.003]
　FAN Lingling,WANG Chenghai.Expression of SFRP2 and MORC2 in Serous Ovarian Cancer and its Prognostic Significance[J].Journal of Medical Information,2026,39(17):16.[doi:10.3969/j.issn.1006-1959.2026.05.003]

更新日期/Last Update: 1900-01-01